Using Stellate Ganglion Block to Prevent Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage
Effect of Early Stellate Ganglion Block for Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage: a Randomized Controlled Trial (BLOCK-CVS)
This study is testing if a special nerve block can help prevent serious complications in people who have had bleeding in the brain from an aneurysm.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 202 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Beijing Tiantan Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Beijing, Beijing) |
| Trial ID | NCT04691271 on ClinicalTrials.gov |
What this trial studies
This study investigates the use of stellate ganglion block (SGB) as a potential intervention to prevent cerebral vasospasm (cVS) following aneurysmal subarachnoid hemorrhage (aSAH). cVS is a significant complication that can lead to delayed cerebral infarction, increasing disability and mortality rates. The trial aims to evaluate the effectiveness of early SGB application in improving outcomes for patients who have experienced aSAH. Participants will be monitored for changes in cerebral blood flow and the incidence of delayed ischemic neurological dysfunction.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18-65 who have experienced aSAH within the last 48 hours and are planning for surgical treatment.
Not a fit: Patients with severe coagulation dysfunction, multiple aneurysms, or specific anatomical issues may not benefit from this intervention.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the risk of delayed cerebral infarction in patients recovering from aneurysmal subarachnoid hemorrhage.
How similar studies have performed: While the use of stellate ganglion block has shown promise in other contexts, this specific application for preventing cerebral vasospasm after aSAH is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age range: 18-65 years old; * Within 48 hours after onset of aSAH,and planning surgical treatment(aneurysm clipping); * Preoperative Hunt-Hess grade 2-3 * Sign informed consent. Exclusion Criteria: * ASA \> grade III; * Patients with posterior circulation aneurysm, ophthalmic aneurysms or internal carotid aneurysms; * patients with multiple aneurysms; * Patients with severe coagulation dysfunction; * Patients with trauma and local infection in the nerve block area; * Local anatomic structure changes (neck structure changes caused by radiotherapy, chemotherapy and surgery); * MCA stenosis or infarction was found by preoperative imaging; * Patients with poor temporal window signal revealed by preoperative TCD (clear waveform image could not be obtained); * Allergy to known local anesthetics; * Pregnant and lactating women.
Where this trial is running
Beijing, Beijing
- Beijing Tiantan Hospital — Beijing, Beijing, China (Recruiting)
Study contacts
- Principal investigator: Ruquan Han, M.D., Ph.D — Beijing Tiantan Hospital
- Study coordinator: Ruquan Han, M.D., Ph.D
- Email: ruquan.han@gmail.com
- Phone: 8610-59976660
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.